OnKure Therapeutics, Inc. Class A OKUR 深 滬
等待開盤 03-26 09:30:00 美东时间
4.00
+0.020
+0.50%
華盛通- 最 高4.10
- 今 開4.00
- 成交量 17.61万股
- 最 低 3.60
- 昨 收 3.98
- 總市值 5419.28万
- 52周最高 4.75
- 市盈率 靜 --
- 換手率 1.30%
- 52周最低 1.70
- 委 比 95.96%
- 總股本 1354.82万
- 歷史最高 19.9992
- 量 比 0.78
- 振 幅 12.56%
- 歷史最低 1.70
- 每 手 1
- 風險率 0.53%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 能源股获大行青睐！美国铝业、康索尔能源、康菲石油、EOG能源等获上调目标价；多只航空股遭下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Altimmune"买入"评级，目标价从12美元升至25美元；BTIG：维持Jade Biosciences"买入"评级，目标价从28美元升至39美元
03-17 11:45
Micron To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Monday
Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratings on analyst ratings page.
03-16 20:12
'[HC Wainwright & Co. Maintains Buy on OnKure Therapeutics, Lowers Price Target to $27
HC Wainwright & Co. analyst Robert Burns maintains OnKure Therapeutics (NASDAQ:OKUR) with a Buy and lowers the price target from $34 to $27.
03-16 19:27
OnKure Therapeutics Q4 EPS $(0.99) Misses $(0.75) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.75) by 32 percent. This is a 27.74 percent increase over losses of $(1.37) per share
03-13 04:16
HC Wainwright & Co. Reiterates Buy on OnKure Therapeutics, Maintains $34 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates OnKure Therapeutics (NASDAQ:OKUR) with a Buy and maintains $34 price target.
2025-08-26 22:34
OnKure Therapeutics Q2 EPS $(1.14) Beats $(1.26) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.14) per share which beat the analyst consensus estimate of $(1.26) by 9.88 percent. This is a 97.46 percent increase over losses of $(44.82) per share
2025-08-13 04:22
OnKure Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Business Update
OnKure Therapeutics reported Q2 2025 financial results and provided updates on its lead asset, OKI-219, a PI3Kα inhibitor. The company has completed enrollment in the monotherapy and fulvestrant combination arms of the PIKture-01 trial and initiated two new triplet arms for HR+ and HER2+ metastatic breast cancer. Data from the monotherapy and fulvestrant combination arms is expected in Q4 2025. OnKure also advanced its pan-mutant selective PI3Kα ...
2025-08-12 20:05
OnKure Therapeutics Updates on PI3Kα Inhibitor Progress
OnKure Therapeutics ( ($OKUR) ) has shared an announcement. On June 26, 2025, O...
2025-06-27 04:49
美股大行评级 | Evercore ISI集团：维持苹果"跑赢大市"评级，目标价从260美元升至275美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1109037475621081088.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Black Diamond Therapeutic(BDTX)"买入"评级，目标价从11美元升至12美元</p> <p>• 康托·菲茨杰拉德：维持Disc Medicin
2025-03-19 09:24
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
Onkure Therapeutics, Inc. (OKUR) has disclosed a new risk, in the Competition c...
2025-03-12 14:00
